1-10 of 10
Keywords: Chemotherapy
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Clin Sci (Lond) (2022) 136 (11): 841–860.
Published: 01 June 2022
... 10 05 2022 11 05 2022 © 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2022 Cancer Cardiotoxicity Chemotherapy Doxorubicin Mitochondria Mitochondrial dynamics Doxorubicin (DOX) is a chemotherapeutic agent that is used...
Clin Sci (Lond) (2020) 134 (21): 2897–2927.
Published: 13 November 2020
... of cancer treatments. Therefore, numerous preclinical studies demonstrate that inhibition of CYP1B1 protects against chemotherapy-induced cardiotoxicity and prevents chemo- and radio-resistance. Most of these studies have utilized phytochemicals to inhibit CYP1B1. Since phytochemicals have multiple targets...
Clin Sci (Lond) (2020) 134 (19): 2595–2622.
Published: 14 October 2020
... The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2020 cardiac arrhythmia cardio-oncology cardiotoxicity chemotherapy heart failure PI3Kα The phosphoinositide 3-kinases (PI3Ks) are a family of intracellular lipid kinases that phosphorylate the 3...
Clin Sci (Lond) (2020) 134 (2): 155–167.
Published: 23 January 2020
.... apoptosis Bim chemotherapy colorectal cancer SPZ1 Colorectal cancer (CRC) originates from the intestinal epithelial cells, and is the third most common malignancy in males and the second most common in females worldwide [ 1 , 2 ]. The pathogenesis of CRC is complex, and the genes involved...
Includes: Supplementary data
Clin Sci (Lond) (2017) 131 (2): 113–121.
Published: 14 December 2016
... that for many malignancies. In fact in the general population mortality is driven by the stage of HF, with stage A HF conferring a 97% 5-year survival rate, whereas stage D HF confers a 20% 5-year survival rate [ 55 ]. The prognosis in patients with chemotherapy-induced HF is even worse, with 2-year mortality...
Clin Sci (Lond) (2002) 102 (4): 417–424.
Published: 12 March 2002
...Robert C. RINTOUL; Tariq SETHI Tumour recurrence following chemotherapy remains a major obstacle to the cure of many cancers. This is exemplified by small-cell lung cancer (SCLC). Host-tumour interactions are central to tumour survival and proliferation. We hypothesized that a factor(s) within...
Clin Sci (Lond) (1997) 92 (4): 385–389.
Published: 01 April 1997
...D. M. K. Keefe; A. G. Cummins; B. M. Dale; D. Kotasek; T. A. Robb; R. E. Sage 1. Mucositis is a common side-effect of chemotherapy which is difficult to assess except by invasive means such as upper gastrointestinal endoscopy. Differential absorption of mono- and di-saccharides, such as rhamnose...
Clin Sci (Lond) (1989) 77 (5): 501–507.
Published: 01 November 1989
... pressure in hypertensive individuals, and the results suggest that DLIF may contribute to the increased blood pressure in some of these subjects. 26 4 1989 3 5 1989 © 1989 The Biochemical Society and the Medical Research Society 1989 chemotherapy fluid retention hypertension (Na...
Clin Sci (Lond) (1984) 66 (2): 147–154.
Published: 01 February 1984
... leukaemia and one patient with chronic myeloid leukaemia before and after chemotherapy. 2. Gas chromatography-mass spectrometry was used to determine plasma [ 15 N]glycine enrichment. Pool sizes and turnover rate constants were estimated from time-decay curves for isotope enrichment. 3. Turnover rate...
Clin Sci Mol Med (1975) 49 (2): 99–106.
Published: 01 August 1975
... of these compounds, which were released in association with liposomal lipid, in draining lymph nodes. 27 11 1974 © 1975 The Biochemical Society and the Medical Research Society 1975 chemotherapy drug therapy liposomes Clinical Science and Molecular Medicine (1975) 49 99-106. Liposomes...